Your new experience awaits. Try the new design now and help us make it even better

ORIGINAL RESEARCH article

Front. Oncol.

Sec. Radiation Oncology

Volume 15 - 2025 | doi: 10.3389/fonc.2025.1673676

125I Seed Brachytherapy with Cement Augmentation versus Cement Alone for Acetabular Metastases: A Comparative Study

Provisionally accepted
Zhiqian  SunZhiqian Sun1,2Shuai  LiShuai Li2Baoquan  ZhuBaoquan Zhu1,2Qiyu  SunQiyu Sun2Min  LiMin Li2*
  • 1Shandong Second Medical University, Weifang, China
  • 2Department of Nuclear Medicine, 960th Hospital of the PLA, Jinan, China

The final, formatted version of the article will be published soon.

Objective As the survival of cancer patients improves, the incidence of bone metastases increases. Acetabular metastases often cause severe pain, limit hip mobility, and impair quality of life. Percutaneous cement augmentation (PCA) provides short-term pain relief and improves mechanical stability, but its anti-tumor effect is limited. 125I seed brachytherapy offers precise local tumor control but cannot enhance bone strength. We proposed a novel strategy combining 125I seeds with cement augmentation to achieve better tumor killing and bone stabilization. Methods We retrospectively analyzed 64 patients (determined by power analysis assuming α=0.05, β=0.2, and expected difference in VAS scores of 1.5) with acetabular metastases who underwent either PCA alone (group A, n=34) or 125I seed brachytherapy plus PCA (group B, n=30) between December 2008 and December 2022. Pain intensity (VAS), functional status (ECOG), and complications were evaluated as primary endpoints before and up to 6 months after treatment. Survival analysis was performed using Kaplan-Meier method with log-rank test. Results The two groups had similar baseline characteristics. Group B showed significantly lower mean VAS scores (mean difference: 2.1; 95% CI: 1.6-2.6; p < 0.001) and ECOG scores (mean difference: 1.51; 95% CI: 1.1-1.9; p < 0.001) at 6 months post-treatment compared to group A. Complication rates were comparable between groups (5.9% vs 3.0%, p = 0.62), with no significant difference in median survival (16.8 vs 16.7 months, p = 0.85). Conclusion Combined ¹²⁵I seed brachytherapy and PCA (¹²⁵I-PCA) provides superior long-term pain control and functional outcomes compared to PCA alone for acetabular metastases. This is attributed to the synergistic effect of PMMA-mediated mechanical stabilization and continuous low-dose radiation-induced tumor suppression, effectively addressing the transient cytoreduction limitation of standalone PCA. Integration of TPS(Treatment Planning System )-guided brachytherapy dosing with precise CT-guided cementoplasty represents an effective and safe palliative strategy for these complex lesions.

Keywords: Acetabulum, Neoplasm metastases, Radioactive 125I particles, Bone cement, Pain

Received: 26 Jul 2025; Accepted: 28 Aug 2025.

Copyright: © 2025 Sun, Li, Zhu, Sun and Li. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

* Correspondence: Min Li, Department of Nuclear Medicine, 960th Hospital of the PLA, Jinan, China

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.